Received this email from a friend? Sign up now |
|---|
 |
|---|
 |
|---|
September 26, 2024 This message includes updates on respiratory viruses from CDC. |
|---|
RSV can be dangerous for babies and older adults. We are entering the second year where RSV immunizations will be available to protect these groups from severe RSV. There is one set of recommendations for older adults, and a separate set – which includes two immunization options – to protect babies. |
|---|
 | RSV Vaccines for Older AdultsCDC recommends a single dose of an RSV vaccine for everyone ages 75 and older and for people ages 60–74 who are at increased risk of severe RSV. Adults ages 60-74 are considered at increased risk if they have one or more of the following risk factors:
*For a complete list of chronic health issues that lead to increased risk of severe RSV, see Clinical Overview of RSV. If you have already gotten an RSV vaccine, you do not need to get another one at this time. How well do these vaccines work? Real-world data gathered during the 2023-2024 RSV season show that RSV vaccines reduced the risk of RSV-associated hospitalization or emergency department visits by 75%-80%. Importantly, these data include populations that are at highest risk for severe RSV, including those ages 75 and older, those who are immunocompromised, and those who live in nursing homes. If you are eligible for an RSV vaccine, the best time to get vaccinated is now (late summer through early fall) – before the RSV season starts! |
|---|
 | RSV Immunizations to Protect InfantsCDC recommends all babies be protected from severe RSV by one of two immunization options:
Most babies will not need both.
Both RSV immunizations to protect infants are administered during specific months, detailed here:
 * For infants born outside of this window (April – September) and for young children who are at increased risk for severe RSV disease and entering their second RSV season, the optimal timing for nirsevimab administration is shortly before the RSV season begins (October or November).
How good are these immunizations at protecting babies? Early real-world data show that nirsevimab was 80-90% effective in preventing babies from being hospitalized with RSV. It provides immediate protection against RSV and lasts at least 5 months.
CDC continues to gather real-world effectiveness data for maternal RSV vaccine (Pfizer’s Abrysvo). Our best data at this time continues to be from the phase 3 clinical trial, which showed the maternal RSV vaccine reduced the risk of the baby being hospitalized for RSV by 68% and the risk of having a healthcare visit for RSV by 57% within 3 months after birth. Additional data shows that maternal antibodies protect the baby against RSV for approximately 6 months after birth.
Whether you're a healthcare provider, a caretaker, or at risk of RSV yourself, you can help fight against RSV by learning and sharing CDC's recommendations with others. |
|---|
Respiratory Virus Data Channel Weekly SnapshotThe Respiratory Virus Weekly Snapshot provides an update on COVID-19, flu, and RSV activity nationally and in your state. Check back every Friday for the latest data. |
|---|
|
|---|
